The Role of Beta-Adrenergic Receptor Blockers in Alzheimer’s Disease: Potential Genetic and Cellular Signaling Mechanisms

According to genetic studies, Alzheimer’s disease (AD) is linked to beta-adrenergic receptor blockade through numerous factors, including human leukocyte antigen genes, the renin–angiotensin system, poly(adenosine diphosphate-ribose) polymerase 1, nerve growth factor, vascular endothelial growth fac...

Full description

Saved in:
Bibliographic Details
Published in:American journal of Alzheimer's disease and other dementias 2013-08, Vol.28 (5), p.427-439
Main Authors: Lương, Khanh vinh quoc, Nguyen, Lan Thi Hoàng
Format: Article
Language:English
Subjects:
Adrenergic beta-Antagonists - pharmacology
Alzheimer Disease - drug therapy
Alzheimer Disease - genetics
Alzheimer Disease - metabolism
Animals
Brain - drug effects
Brain - metabolism
Humans
Neurons - drug effects
Neurons - metabolism
Receptors, Adrenergic, beta - metabolism
Reviews
Signal Transduction - drug effects
Signal Transduction - genetics
Citations: Items that this one cites
Online Access:Request full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:According to genetic studies, Alzheimer’s disease (AD) is linked to beta-adrenergic receptor blockade through numerous factors, including human leukocyte antigen genes, the renin–angiotensin system, poly(adenosine diphosphate-ribose) polymerase 1, nerve growth factor, vascular endothelial growth factor, and the reduced form of nicotinamide adenine dinucleotide phosphate. Beta-adrenergic receptor blockade is also implicated in AD due to its effects on matrix metalloproteinases, mitogen-activated protein kinase pathways, prostaglandins, cyclooxygenase-2, and nitric oxide synthase. Beta-adrenergic receptor blockade may also have a significant role in AD, although the role is controversial. Behavioral symptoms, sex, or genetic factors, including Beta 2-adrenergic receptor variants, apolipoprotein E, and cytochrome P450 CYP2D6, may contribute to beta-adrenergic receptor blockade modulation in AD. Thus, the characterization of beta-adrenergic receptor blockade in patients with AD is needed.
ISSN:1533-3175
1938-2731
DOI:10.1177/1533317513488924